HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Howell, M. Articles by Foegh, M. Search for Related Content PubMed Articles by Howell, M. Articles by Foegh, M.

Lanreotide, a somatostatin analogue, reduces insulin-like growth factor I accumulation in proliferating aortic tissue in rabbits in vivo. A preliminary study

Howell M, Ørskov H, Frystyk J. Flyvbjerg A, Grønbæk H, Foegh M. Lanreotide, a somatostatin analogue, reduces insulin-like growth factor I accumulation in proliferating aortic tissue in rabbits in vivo. A preliminary study. Eur J Endocrinol 1994;130:422–5. ISSN 0804–4643

Coronary artery restenosis following percutaneous transluminal angioplasty occurs with a very high incidence. Major efforts have been aimed at revealing the mechanisms and at developing therapies that might prevent or delay the myointimal proliferation. Most clinical trials have been unsuccessful. Endothelial denudation was induced in 30 rabbits using balloon catheterization of iliac arteries and aorta. Immunoreactive insulin-like growth factor I (IGF-I) was measured in arterial tissue samples obtained 1, 2 and 4 days postoperatively using a double extraction procedure to remove IGF-I binding proteins. Half of the animals were treated with subcutaneous injections of lanreotide, 10 µg/kg twice daily, and the other half served as controls. In the latter group, arterial IGF-I was unaltered from baseline at day 1 and increased by 300 and 400% at days 2 and 4. No increase was observed in the rabbits treated with lanreotide. The results indicate that initial local accumulation of IGF-I may be one of the mechanisms involved in myointimal proliferation after experimental arterial injury. The reduction of local IGF-I accumulation by lanreotide may be involved in the previously observed reduction in myointimal proliferation.

Hans Ørskov, Institute of Experimental Clinical Research, University Hospital, DK-8000 Aarhus C, Denmark

This article has been cited by other articles:

				J. Frystyk, T. Ledet, N. Moller, A. Flyvbjerg, and H. Orskov Cardiovascular Disease and Insulin-Like Growth Factor I Circulation, August 20, 2002; 106(8): 893 - 895. [Full Text] [PDF]

				S. Saito, N. Motomura, H. Lou, P. W. Ramwell, M. L. Foegh, DSc, Sponsor:, and E. A. Lefrak SPECIFIC EFFECTS OF ESTROGEN ON GROWTH FACTOR AND MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II ANTIGEN EXPRESSION IN RAT AORTIC ALLOGRAFT J. Thorac. Cardiovasc. Surg., November 1, 1997; 114(5): 803 - 810. [Abstract] [Full Text]

				M. K. Hong, K. M. Kent, R. Mehran, G. S. Mintz, F. O. Tio, M. Foegh, S. C. Wong, S. S. Cathapermal, and M. B. Leon Continuous Subcutaneous Angiopeptin Treatment Significantly Reduces Neointimal Hyperplasia in a Porcine Coronary In-Stent Restenosis Model Circulation, January 21, 1997; 95(2): 449 - 454. [Abstract] [Full Text]

				J. Frystyk, C. Skjærbæk, N. Alexander, H. Emanuelsson, H. Suryapranata, H. Beyer, M. Foegh, and H. Orskov Lanreotide Reduces Serum Free and Total Insulin-Like Growth Factor-I After Angioplasty Circulation, November 15, 1996; 94(10): 2465 - 2471. [Abstract] [Full Text]

				H. Emanuelsson, K. J. Beatt, J.-P. Bagger, R. Balcon, J. Heikkila, J. Piessens, M. Schaeffer, H. Suryapranata, M. Foegh, and f. t. E. A. S. Group Long-term Effects of Angiopeptin Treatment in Coronary Angioplasty : Reduction of Clinical Events but Not Angiographic Restenosis Circulation, March 15, 1995; 91(6): 1689 - 1696. [Abstract] [Full Text]